Brisbane, Australia-based oral appliance marketer Oventus Medical Ltd’s Sleep Treatment Platform will be included in a range of obstructive sleep apnea (OSA) treatment solutions sold by US durable medical equipment (DME) supplier Aeroflow Healthcare Inc.
Aeroflow is a provider of DME selling CPAP and associated products and services. It is targeting nationwide expansion and has identified OSA therapeutics as a key growth driver. Aeroflow has identified 7 of its sites in North Carolina, South Carolina, Tennessee, Alabama, Colorado, Virginia, and Michigan for an initial launch. After, Aeroflow intends to launch across the United States.
Under the agreement, Oventus’ Sleep Treatment Platform, which includes the O2Vent Optima oral appliance and consumables will be introduced by Aeroflow throughout its locations, direct-to-consumer e-commerce platform, and via agreements with referring sleep clinics across the Southeastern US states.
In addition, Aeroflow has signed a master agreement with Oventus that will see it offer Oventus products under subcontracts with regional sleep groups across the United States.
In line with other Oventus agreements there are minimum quotas of 20 patients to be treated with the O2Vent Optima per site, per month, once fully operational.
Oventus CEO Chris Hart, MPhil, BSc, BDSc, says in a release, “Oventus and Aeroflow are aligned through our ambitious growth targets and shared interest in providing the best available care to patients. This agreement will see Oventus products rolled out initially across the southeast and then nationally as part of Aeroflow’s US expansion plans. Our common targets and values make us great growth partners.”
Casey Hite, CEO of Aeroflow, says, “We are pleased to partner with Oventus as we feel the O2Vent Airway Technology will offer something unique that our patient and clinician community has been unable to access before now. It is a compelling solution for patients that cannot tolerate CPAP or don’t desire it as a treatment option.”
Eric Mongeau, national sales director of Aeroflow, says in a release, “We have been very selective about our growth strategies. Sleep medicine is a core growth area for Aeroflow. We are building a care continuum that will ensure long-term patient adherence regardless of modality. We believe that Oventus brings a market differential to the treatment of OSA. Our companies are well aligned and share a common mission of improving patient outcomes. Multiple locations have been identified with the first group planned to launch in the MidSouth region on 1 April 2020.”
The Oventus-Aeroflow agreement has a term of 3 years, with an automatic 3 year renewal, unless a party elects not to renew no later than 180 days prior to the end of the 3 year period.